Evaluation of ovarian reserve and the assisted reproductive technology (ART) cycles' outcome as well as the relapse rate within one year after ART in women with multiple sclerosis: a case-control study

• Published in: Journal of ovarian research 2024-08, Vol.17 (1), p.165-10, Article 165
• Main Authors: Arabipoor, Arezoo, Moini, Ashraf, Nabavi, Seyed Massood, Mohiti, Shima, Mashayekhi, Mehri, Zolfaghari, Zahra
• Format: Article
• Language: English
• Subjects: Adult; anti-Müllerian hormone serum level; Biological response modifiers; Care and treatment; Case-Control Studies; Diseases; Female; Follicle-stimulating hormone; Glycoproteins; Health aspects; Humans; Infertility treatment cycle; Infertility, Female - therapy; Interferon; Multiple sclerosis; Multiple Sclerosis - drug therapy; Multiple Sclerosis - physiopathology; Ovarian Reserve; Pregnancy; Recurrence; Relapse; Reproductive Techniques, Assisted; Reproductive technology; Retrospective Studies; Treatment Outcome; Women
• ISSN: 1757-2215; 1757-2215
• DOI: 10.1186/s13048-024-01483-4

To compare the ovarian reserve and the results of infertility treatment, as well as to investigate the relapse rate in the first year after the assisted reproductive technology (ART) cycle in patients with multiple sclerosis (MS) referred to Royan Institute. This retrospective study was carried out to evaluate all women diagnosed with MS and referred to Royan Institute for assessment and treatment of possible infertility between 2011 and 2022. The control group consisted of randomly selected healthy women with tubal factor infertility who were referred for treatment during the same time period and matched in terms of age. A comparison was made between groups in terms of ovarian reserve and infertility treatment outcomes. Additionally, patients with MS who met the criteria were monitored via telephone to evaluate the symptoms, disability and relapse rate both pre- and post-ART. Over the course of a decade, the database documented a total of 60 cases diagnosed with MS. Upon examination of the records, it was found that in 27 patients only admission was done without any hormonal assessment or infertility treatment cycle and 5 patients proceeded with the intrauterine insemination cycle. Eventually, 28 women with MS underwent the ART cycle and all of them were treated with interferon beta, glatiramer acetate, or some oral disease modifying therapies. No statistically significant difference in terms of the basal levels of luteinizing hormone, follicle-stimulating hormone and anti-Müllerian hormone was found between the MS and control groups (P > 0.05). Two groups were comparable in terms of menstrual status. The study revealed that both groups exhibited similarities in terms of the controlled ovarian stimulation protocol and duration, the dosage of gonadotropin administered, as well as the ovarian response type, clinical pregnancy rate, and live birth rate (P > 0.05). After follow up, only 2 patients (9.5%) reported relapse of symptoms within one year after ART. The ovarian reserve and ovarian stimulation cycle and pregnancy outcomes following the ART cycle in MS patients were similar to the age-matched control group. The relapse rate of multiple sclerosis did not show a significant increase within a year following the ART cycle.